KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) EBT (2016 - 2025)

Boston Scientific (BSX) has disclosed EBT for 17 consecutive years, with $700.0 million as the latest value for Q4 2025.

  • Quarterly EBT rose 19.66% to $700.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 billion through Dec 2025, up 48.33% year-over-year, with the annual reading at $3.4 billion for FY2025, 48.33% up from the prior year.
  • EBT hit $700.0 million in Q4 2025 for Boston Scientific, down from $939.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $941.0 million in Q2 2025 to a low of $119.0 million in Q4 2021.
  • Historically, EBT has averaged $493.5 million across 5 years, with a median of $463.5 million in 2021.
  • Biggest YoY gain for EBT was 1377.27% in 2021; the steepest drop was 61.24% in 2021.
  • Year by year, EBT stood at $119.0 million in 2021, then soared by 232.77% to $396.0 million in 2022, then grew by 27.53% to $505.0 million in 2023, then rose by 15.84% to $585.0 million in 2024, then grew by 19.66% to $700.0 million in 2025.
  • Business Quant data shows EBT for BSX at $700.0 million in Q4 2025, $939.0 million in Q3 2025, and $941.0 million in Q2 2025.